Therefore, CCL2, CCR1, CXCL10, CXCL11, and IL2RG might be involved in neoadjuvant chemotherapy in breast cancer via the cytokine–cytokine receptor interaction pathway. This evidence concerns the gene IL2RG and breast carcinoma.